An announcement from Opthea Limited ( (AU:OPT) ) is now available.
Opthea Limited reported its half-year financial results, highlighting a cash reserve of $131.9 million, which is expected to support the company through key clinical milestones in 2025. The company is advancing its Phase 3 trials for sozinibercept, a promising treatment for wet AMD, and preparing for a potential FDA submission. Recent corporate developments include strategic appointments and successful capital raising, positioning Opthea for potential growth and impact in the biopharmaceutical industry.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD). Their primary product, sozinibercept, is designed to improve vision in patients who do not respond well to existing treatments.
YTD Price Performance: 9.09%
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $710.5M
See more data about OPT stock on TipRanks’ Stock Analysis page.